Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

KZIA

Kazia Therapeutics Limited ADR

Last Close
May 21 • 09:52AM ET
0.2694
Dollar change
-0.0056
Percentage change
-2.04 		%
Scroll to Statements
Index- P/E- EPS (ttm)-0.44 Insider Own- Shs Outstand23.63M Perf Week-7.04%
Market Cap6.37M Forward P/E- EPS next Y- Insider Trans- Shs Float23.62M Perf Month-28.54%
Income-10.40M PEG- EPS next Q- Inst Own1.62% Short Float0.36% Perf Quarter-14.50%
Sales0.00M P/S- EPS this Y- Inst Trans25.73% Short Ratio0.11 Perf Half Y-67.22%
Book/sh0.14 P/B1.98 EPS next Y- ROA-58.59% Short Interest0.09M Perf Year-78.62%
Cash/sh0.10 P/C2.62 EPS next 5Y- ROE-181.74% 52W Range0.19 - 1.34 Perf YTD-38.70%
Dividend Est.- P/FCF- EPS past 5Y4.22% ROI-289.47% 52W High-79.90% Beta2.06
Dividend TTM- Quick Ratio0.71 Sales past 5Y-20.00% Gross Margin- 52W Low44.37% ATR (14)0.04
Dividend Ex-Date- Current Ratio0.71 EPS Y/Y TTM64.58% Oper. Margin0.00% RSI (14)39.96 Volatility15.54% 12.44%
Employees- Debt/Eq0.07 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price2.00
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q61.57% Payout- Rel Volume0.30 Prev Close0.28
Sales Surprise- EPS Surprise- Sales Q/Q- Earnings- Avg Volume788.57K Price0.27
SMA20-13.40% SMA50-13.29% SMA200-49.99% Trades Volume24,529 Change-2.04%
Date Action Analyst Rating Change Price Target Change
Oct-14-21Initiated Maxim Group Buy $18
Jan-05-21Initiated H.C. Wainwright Buy $17
Today 07:39AM
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
(InvestorPlace)
May-02-24 04:22AM
Kazia concludes first stage of Phase I advanced cancer treatment trial
(Clinical Trials Arena) -5.42%
May-01-24 08:45AM
KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTS
(PR Newswire) -10.78%
Mar-24-24 07:55AM
11 Best ASX Stocks To Buy Now
(Insider Monkey)
Mar-21-24 08:52AM
Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases
(PR Newswire) -8.89%
08:00AM Loading…
Mar-13-24 08:00AM
Kazia announces presentation of new data at AACR Annual Meeting
(PR Newswire) +8.36%
Feb-21-24 07:30AM
Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint
(PR Newswire) -20.61%
Jan-18-24 07:30AM
KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS
(PR Newswire)
Dec-05-23 06:02PM
Kazia Therapeutics Announces Closing of $2 Million Registered Direct Offering
(PR Newswire)
Dec-01-23 08:00AM
Kazia Therapeutics Announces $2 Million Registered Direct Offering
(PR Newswire) -19.56%
Nov-29-23 07:01AM
KAZIA ANNOUNCES NON-BINDING LETTER OF INTENT FOR THE PROPOSED GRANTING OF RIGHTS TO DEVELOP AND COMMERCIALIZE PAXALISIB OUTSIDE OF ONCOLOGY
(PR Newswire) -6.34%
Nov-21-23 07:30AM
KAZIA PROVIDES OVERVIEW OF PAXALISIB RELATED PRESENTATIONS FROM THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING
(PR Newswire) -10.59%
Nov-20-23 04:30PM
KAZIA ANNOUNCES RECEIPT OF NASDAQ MINIMUM BID NOTIFICATION
(PR Newswire) -6.11%
Nov-15-23 08:30AM
KAZIA ANNOUNCES THE RELEASE OF PNOC022 CLINICAL STUDY ABSTRACT HIGHLIGHTING PAXALISIB IN DIFFUSE MIDLINE GLIOMA PATIENTS AHEAD OF THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING
(PR Newswire)
Nov-10-23 07:01AM
KAZIA ANNOUNCES PUBLICATION IN MOLECULAR CANCER THERAPEUTICS HIGHLIGHTING PAXALISIB PRECLINICAL DATA IN MELANOMA
(PR Newswire)
07:01AM Loading…
Nov-01-23 07:01AM
KAZIA THERAPEUTICS PROVIDES PRELIMINARY UPDATE FROM ONGOING PHASE 2 STUDY OF PAXALISIB IN PRIMARY CNS LYMPHOMA
(PR Newswire)
Oct-23-23 07:01AM
KAZIA THERAPEUTICS ANNOUNCES CLINICAL DATA AT ESMO 2023 FROM ONGOING PHASE 1 EVT801 STUDY
(PR Newswire) -5.29%
Oct-11-23 07:01AM
Kazia announces voluntary delisting from ASX
(PR Newswire) -15.78%
Oct-05-23 07:01AM
KAZIA THERAPEUTICS ANNOUNCES PRESENTATIONS AT UPCOMING SCIENTIFIC MEETINGS
(PR Newswire)
Sep-29-23 07:01AM
KAZIA THERAPEUTICS ANNOUNCES ACCEPTANCE OF LATE-BREAKING ABSTRACT AND ORAL PRESENTATION OF PNOC022 CLINICAL DATA AT 2023 SOCIETY FOR NEURO-ONCOLOGY ANNUAL MEETING
(PR Newswire) -5.21%
Jul-06-23 07:00AM
KAZIA'S PAXALISIB RECEIVES FAST TRACK DESIGNATION FROM FDA FOR TREATMENT OF SOLID TUMOR BRAIN METASTASES HARBORING PI3K PATHWAY MUTATIONS IN COMBINATION WITH RADIATION THERAPY
(PR Newswire) -8.55%
Jun-08-23 07:00AM
KAZIA THERAPEUTICS ANNOUNCES PHASE II CLINICAL STUDY TO INVESTIGATE PAXALISIB IN RECURRENT/PROGRESSIVE IDH-MUTANT GRADE 2 & 3 GLIOMA
(PR Newswire)
May-25-23 07:01AM
KAZIA CEO, DR. JOHN FRIEND TO PARTICIPATE IN WHITE HOUSE CANCER MOONSHOT
(PR Newswire)
Apr-14-23 07:01AM
KAZIA REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT
(PR Newswire) +9.09%
Apr-04-23 07:00AM
KAZIA PRESENTS NEW DATA FOR PAXALISIB AND EVT801 AT AACR ANNUAL MEETING
(PR Newswire) +6.86%
Jan-25-23 03:03PM
Trade Alert: Stephen Abolakian At Kazia Therapeutics Limited (ASX:KZA), Has Just Spent AU$1m Buying 54% More Shares
(Simply Wall St.) -5.81%
Jan-18-23 11:50AM
Kazia Therapeutics CEO talks $4.5 million capital raise
(News Direct) +5.28%
Jan-16-23 07:01AM
KAZIA RAISES A$4.5 MILLION TO PROGRESS R&D PROGRAMS
(PR Newswire)
Dec-19-22 09:00PM
Kazia Therapeutics (KZIA): Collaboration May Expand Utility to Combo Therapies
(ACCESSWIRE)
Dec-15-22 07:01AM
KAZIA LAUNCHES PRECLINICAL COLLABORATION WITH QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE AND ANNOUNCES PATENT FILING
(PR Newswire)
07:01AM Loading…
Dec-12-22 07:01AM
KAZIA ANNOUNCES RECEIPT OF NASDAQ MINIMUM BID NOTIFICATION
(PR Newswire)
Dec-01-22 07:01AM
COMPELLING PRECLINICAL DATA FOR KAZIA'S EVT801 PUBLISHED IN PEER-REVIEWED CANCER RESEARCH JOURNAL
(PR Newswire) +5.20%
Nov-28-22 04:50PM
Quite a few insiders invested in Kazia Therapeutics Limited (ASX:KZA) last year which is positive news for shareholders
(Simply Wall St.)
Nov-09-22 07:00AM
KAZIA TO PRESENT PAXALISIB DATA IN ADULT AND PEDIATRIC BRAIN CANCER AT SOCIETY FOR NEURO-ONCOLOGY ANNUAL MEETING
(PR Newswire)
Nov-02-22 07:10AM
Kazia Therapeutics (KZIA): Q123 Cash Flows in Line with Our Estimates
(ACCESSWIRE) +5.68%
Oct-27-22 10:48AM
Kazia Therapeutics Reveals Paxalisib Preclinical Data In Melanoma Animal Models
(Benzinga)
07:00AM
KAZIA'S PAXALISIB DEMONSTRATES POSITIVE MONOTHERAPY EFFICACY SIGNALS IN PRECLINICAL MODELS OF MELANOMA
(PR Newswire)
Oct-06-22 08:00AM
PNOC CLINICAL STUDY OF KAZIA'S PAXALISIB IN CHILDHOOD BRAIN CANCER EXPANDS INTERNATIONALLY
(PR Newswire) -11.48%
Sep-26-22 09:55AM
Novogen Limited (KZIA) Could Find Support Soon, Here's Why You Should Buy the Stock Now
(Zacks)
Sep-09-22 08:00AM
KAZIA THERAPEUTICS TO PRESENT AT HC WAINWRIGHT 24th ANNUAL GLOBAL INVESTMENT CONFERENCE
(PR Newswire)
Sep-08-22 06:00PM
KAZIA TO PRESENT FINAL DATA FROM PAXALISIB PHASE II STUDY IN GLIOBLASTOMA AT ESMO
(PR Newswire)
Sep-07-22 10:35AM
Kazia Therapeutics (KZIA): Doubling Down on Clinical Development
(ACCESSWIRE)
Aug-11-22 09:55AM
Here's Why Novogen Limited (KZIA) Is a Great 'Buy the Bottom' Stock Now
(Zacks)
Aug-05-22 10:00AM
Kazia Therapeutics Shares Jump On Interim Data From Paxalisib Combo Study In Brain Metastases
(Benzinga)
08:40AM
KAZIA THERAPEUTICS REPORTS PROMISING INTERIM DATA FROM COMBINATION STUDY OF PAXALISIB WITH RADIOTHERAPY IN TREATMENT OF BRAIN METASTASES
(PR Newswire)
Aug-01-22 07:00AM
Kazia Shares Tumble After Update From Pivotal Brain Tumor Trial
(Benzinga) -47.11%
Jul-17-22 06:28PM
Kazia Therapeutics (ASX:KZA) Is In A Strong Position To Grow Its Business
(Simply Wall St.)
Jul-12-22 08:15AM
KAZIA LAUNCHES NEW SCIENTIFIC ADVISORY BOARD COMPRISED OF WORLD-LEADING EXPERTS IN BRAIN CANCER
(PR Newswire)
Jul-06-22 07:00AM
US FDA AWARDS RARE PEDIATRIC DISEASE DESIGNATION (RPDD) TO PAXALISIB FOR AT/RT, A RARE FORM OF CHILDHOOD BRAIN CANCER
(PR Newswire)
Jun-17-22 08:00AM
US FDA AWARDS ORPHAN DRUG DESIGNATION (ODD) TO PAXALISIB FOR AT/RT, A RARE FORM OF CHILDHOOD BRAIN CANCER
(PR Newswire)
Jun-13-22 07:00AM
POSITIVE DATA FOR PAXALISIB IN TWO CHILDHOOD BRAIN CANCERS PRESENTED AT 20TH ISPNO ANNUAL MEETING
(PR Newswire) -5.47%
Jun-08-22 08:49PM
Quite a few insiders invested in Kazia Therapeutics Limited (ASX:KZA) last year which is positive news for shareholders
(Simply Wall St.) +5.58%
Jun-07-22 07:00AM
PHASE II STUDY OF PAXALISIB IN BRAIN METASTASES ADVANCES TO EXPANSION STAGE IN BREAST CANCER BRAIN METASTASES COHORT
(PR Newswire)
Jun-03-22 07:00AM
KAZIA PRESENTS POSITIVE FINAL DATA FROM PHASE II STUDY OF PAXALISIB IN NEWLY DIAGNOSED GLIOBLASTOMA AT ASCO CONFERENCE
(PR Newswire)
May-31-22 07:00AM
GBM AGILE OPENS TO PAXALISIB IN EUROPE
(PR Newswire)
May-26-22 07:50AM
Kazia Therapeutics (KZIA): Deep Dive Into Childhood Brain Cancer
(ACCESSWIRE)
May-23-22 08:30AM
KAZIA THERAPEUTICS TO PRESENT AT UPCOMING INVESTOR CONFERENCES HOSTED BY HC WAINWRIGHT AND LD MICRO
(PR Newswire)
May-17-22 08:00AM
KAZIA MARKS DIPG AWARENESS DAY; NEW PRECLINICAL DATA IN DIPG TO BE PRESENTED AT ISPNO CONFERENCE
(PR Newswire) +8.41%
May-16-22 09:12PM
Investing in Kazia Therapeutics (ASX:KZA) three years ago would have delivered you a 69% gain
(Simply Wall St.)
Apr-29-22 11:00AM
KAZIA TO PRESENT FINAL DATA FROM PAXALISIB PHASE II STUDY IN GLIOBLASTOMA AT ASCO
(PR Newswire)
Apr-08-22 08:30AM
KAZIA THERAPEUTICS ANNOUNCES PRECLINICAL DATA PRESENTED AT AACR CONFERENCE BY JOHNS HOPKINS UNIVERSITY SHOWING ACTIVITY OF PAXALISIB IN PAEDIATRIC BRAIN TUMOURS
(PR Newswire)
08:00AM
TWO ABSTRACTS AT AACR CONFERENCE PRESENT DETAILED STUDY DESIGN AND INNOVATIVE BIOMARKER STRATEGY FOR ONGOING PHASE I STUDY OF EVT801 IN ADVANCED CANCER
(PR Newswire)
Mar-30-22 07:35AM
Kazia TherapeuticsTrust (KZIA): Several Upcoming Catalysts
(ACCESSWIRE)
Mar-28-22 05:46AM
When Can We Expect A Profit From Kazia Therapeutics Limited (ASX:KZA)?
(Simply Wall St.)
Mar-21-22 08:00AM
KAZIA TO PRESENT AT UPCOMING INVESTOR CONFERENCE AND AACR ANNUAL SCIENTIFIC MEETING
(PR Newswire)
Feb-28-22 08:00AM
PHASE II CLINICAL STUDY AT WEILL CORNELL MEDICAL CENTER INVESTIGATING PAXALISIB IN COMBINATION WITH METFORMIN AND A KETOGENIC DIET ENROLLS FIRST PATIENT
(PR Newswire)
Feb-07-22 02:25PM
We Think Kazia Therapeutics (ASX:KZA) Can Easily Afford To Drive Business Growth
(Simply Wall St.) +6.53%
08:00AM
KAZIA THERAPEUTICS TO PRESENT AT BIO CEO CONFERENCE
(PR Newswire)
Jan-25-22 08:00AM
KAZIA THERAPEUTICS TO PARTICIPATE IN EDISON GROUP'S GLOBAL HEALTHCARE 'OPEN HOUSE' VIRTUAL CONFERENCE
(PR Newswire)
Jan-07-22 08:00AM
KAZIA THERAPEUTICS TO PRESENT AT HC WAINWRIGHT BIOCONNECT CONFERENCE
(PR Newswire)
Dec-24-21 02:33PM
Independent Non-Executive Director Steven Coffey Just Bought 12% More Shares In Kazia Therapeutics Limited (ASX:KZA)
(Simply Wall St.)
Dec-13-21 11:00AM
KAZIA THERAPEUTICS APPOINTS KAREN KRUMEICH AS CHIEF FINANCIAL OFFICER
(PR Newswire)
Dec-04-21 08:00AM
Kazia Announces Positive Final Data From Phase II Clinical Study Of Paxalisib In Newly Diagnosed Glioblastoma
(PR Newswire)
Nov-29-21 08:00AM
GBM AGILE Opens to Paxalisib in Canada
(PR Newswire)
Nov-28-21 09:47PM
Multiple insiders bought Kazia Therapeutics Limited (ASX:KZA) stock earlier this year, a positive sign for shareholders
(Simply Wall St.)
Nov-15-21 11:00AM
Kazia Therapeutics Appoints John Friend, MD, as Chief Medical Officer
(PR Newswire)
Nov-11-21 08:00AM
PNOC Study in Childhood Brain Cancer Enrols First Patient
(PR Newswire)
Nov-04-21 08:00AM
Kazia Enrols First Patient to EVT801 Phase I Clinical Trial
(PR Newswire)
Nov-03-21 08:38PM
Kazia Enrols First Patient to EVT801 Phase I Clinical Trial
(PR Newswire)
Oct-14-21 11:15AM
Kazia TherapeuticsTrust (KZIA): Multiple Paxalisib Data Points Expected in Q4
(ACCESSWIRE)
Oct-13-21 05:42PM
What Kind Of Investors Own Most Of Kazia Therapeutics Limited (ASX:KZA)?
(Simply Wall St.)
Oct-06-21 10:00AM
Kazia Therapeutics to Present at LD Micro Main Event
(PR Newswire)
Sep-10-21 12:30PM
Kazia Therapeutics to Present at HC Wainwright 23rd Annual Global Investment Conference
(PR Newswire)
Sep-07-21 06:36PM
Investing in Kazia Therapeutics (ASX:KZA) three years ago would have delivered you a 241% gain
(Simply Wall St.)
Aug-02-21 05:31PM
When Will Kazia Therapeutics Limited (ASX:KZA) Breakeven?
(Simply Wall St.)
Jul-21-21 10:00AM
Kazia Calls for Increased Focus on Brain Cancer Research this GBM Awareness Day
(PR Newswire)
Jun-30-21 10:00AM
Kazia Provides Progress Update on Paxalisib and EVT801 Clinical Programs
(PR Newswire)
Jun-16-21 03:36PM
How Many Kazia Therapeutics Limited (ASX:KZA) Shares Did Insiders Buy, In The Last Year?
(Simply Wall St.)
Jun-15-21 10:00AM
Kazia Enters Clinical Collaboration With Cornell University for Phase II Clinical Study Using Paxalisib in Combination With Ketogenic Diet for Glioblastoma
(PR Newswire)
Jun-07-21 08:00AM
Study of Paxalisib in Primary CNS Lymphoma at Dana-Farber Cancer Institute Enrols First Patient
(PR Newswire)
Jun-03-21 07:00AM
Kazia Therapeutics to Present at LD Micro Invitational XI
(PR Newswire)
May-02-21 07:52PM
Kazia Therapeutics (ASX:KZA) Is In A Good Position To Deliver On Growth Plans
(Simply Wall St.)
Apr-30-21 08:00PM
The eggs files: why hens are at the centre of modern science
(Financial Times)
Apr-20-21 11:35AM
Kazia Therapeutics (KZIA): New asset to target tumor lymphangiogenesis
(ACCESSWIRE)
Apr-19-21 05:54AM
Kazia Licenses Global Rights to EVT801, a Novel, First-in-Class, Clinic-Ready, VEGFR3 Inhibitor, from Evotec SE
(PR Newswire)
Mar-30-21 07:40AM
Kazia Therapeutics (KZIA): Paxalisib Chinese Rights Licensed
(ACCESSWIRE) -6.38%
Mar-29-21 06:49AM
Kazia Therapeutics Stock Is Trading Higher On Paxalisib Licensing Agreement In Greater China
(Benzinga) +15.65%
05:43AM
Kazia Licenses Rights to Paxalisib in Greater China to Simcere, a Leading Chinese Pharmaceutical Company
(PR Newswire)
Mar-17-21 06:07PM
What Type Of Shareholders Own The Most Number of Kazia Therapeutics Limited (ASX:KZA) Shares?
(Simply Wall St.)
Mar-01-21 06:00PM
Kazia Licenses Cantrixil, a Clinical-stage, First-in-class Ovarian Cancer Drug Candidate, to Oasmia Pharmacetical AB
(PR Newswire) +5.01%
Kazia Therapeutics Ltd. is a clinical stage oncology company, which engages in the pharmaceutical research and development business. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.